Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Equity Average (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Equity Average for 8 consecutive years, with $1.6 billion as the latest value for Q1 2026.

  • For Q1 2026, Equity Average rose 92.33% year-over-year to $1.6 billion; the TTM value through Mar 2026 reached $1.6 billion, up 92.33%, while the annual FY2025 figure was $1.2 billion, 96.27% up from the prior year.
  • Equity Average hit $1.6 billion in Q1 2026 for Kymera Therapeutics, up from $1.3 billion in the prior quarter.
  • Across five years, Equity Average topped out at $1.6 billion in Q1 2026 and bottomed at $395.3 million in Q4 2023.
  • Average Equity Average over 5 years is $701.5 million, with a median of $553.1 million recorded in 2024.
  • Year-over-year, Equity Average dropped 21.19% in 2023 and then skyrocketed 118.66% in 2024.
  • Kymera Therapeutics' Equity Average stood at $501.5 million in 2022, then fell by 21.19% to $395.3 million in 2023, then surged by 118.66% to $864.3 million in 2024, then soared by 46.13% to $1.3 billion in 2025, then increased by 23.49% to $1.6 billion in 2026.
  • According to Business Quant data, Equity Average over the past three periods came in at $1.6 billion, $1.3 billion, and $958.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.